Eagle's Eye View: Your Weekly CV Update From ACC.org Colchicine vs. Placebo in Reducing CV Events; DOACs vs. Warfarin After TAVR; CSP vs. BiVP and Echo Response
May 21, 2025
Delve into the fascinating role of colchicine in reducing serious cardiovascular events, like heart attacks, in patients with vascular disease. Discover the latest findings comparing direct oral anticoagulants to warfarin for those recovering from TAVR procedures. Finally, explore the advantages of conduction system pacing over traditional biventricular pacing for improving heart function and echocardiographic responses. Tune in for these invaluable insights into cardiovascular care!
AI Snips
Chapters
Transcript
Episode notes
DOACs Safer Than Warfarin Post-TAVR
- Direct oral anticoagulants (DOACs) show better bleeding outcomes than warfarin after TAVR.
- DOACs also demonstrate lower all-cause mortality, making them preferable over warfarin in these patients.
Colchicine Lowers Cardiovascular Events
- Meta-analyses show colchicine reduces major adverse cardiovascular events by 12-25%.
- It lowers myocardial infarction and stroke risk but does not reduce overall mortality consistently.
Cautious Colchicine Use in Practice
- Use colchicine cautiously, mainly for patients with recurrent cardiovascular events despite guideline therapy.
- Consider colchicine in patients with high inflammation markers such as HSCRP indicating persistent inflammation.